



# SAFETY DATA SHEET

Revision date: 19-Nov-2014

Version: 5.1

Page 1 of 7

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** TRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection

**Trade Name:** TRUMENBA  
**Compound Number:** PF-05212366  
**Synonyms:** TRUMENBA- neisseria meningitidis serogroup b recombinant lp2086 a05 protein variant antigen and neisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen injection, suspension ; PF-05212366 (Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein [rLP2086; subfamily A and B; E coli] Vaccine); rLP2086; MnBvLP2086  
**Chemical Family:** Not determined

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Vaccine

### Details of the Supplier of the Safety Data Sheet

**Pfizer Inc**  
**Pfizer Pharmaceuticals Group**  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

**Pfizer Ltd**  
**Ramsgate Road**  
**Sandwich, Kent**  
**CT13 9NJ**  
**United Kingdom**  
**+00 44 (0)1304 616161**  
**Emergency telephone number:**  
**International CHEMTREC (24 hours): +1-703-527-3887**

**Emergency telephone number:**  
**CHEMTREC (24 hours): 1-800-424-9300**  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

**GHS - Classification** Not classified as hazardous

### EU Classification:

EU Indication of danger: Not classified

### Label Elements

**Other Hazards** No data available  
**Australian Hazard Classification (NOHSC):** Non-Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION / INFORMATION ON INGREDIENTS

## SAFETY DATA SHEET

Material Name: TRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection  
Revision date: 19-Nov-2014

Page 2 of 7

Version: 5.1

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Polysorbate 80	9005-65-6	Not Listed	Not Listed	Not Listed	*
L-Histidine	71-00-1	200-745-3	Not Listed	Not Listed	*
MnBrLP2086	Proprietary	Not Listed	Not Listed	Not Listed	*
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	Not Listed	*

#### Additional Information:

\* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** No data available

**Medical Conditions Aggravated by Exposure:** None known

#### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

#### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

#### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

## SAFETY DATA SHEET

Material Name: TRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection  
Revision date: 19-Nov-2014

Page 3 of 7

Version: 5.1

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Restrict access to work area. Avoid open handling. Minimize generating airborne mists and vapors. Use process containment, local exhaust ventilation or perform work under fume hood/fume cupboard. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

**Specific end use(s):** Vaccine

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### L-Histidine

Latvia OEL - TWA 5 mg/m<sup>3</sup>

#### SODIUM CHLORIDE

Latvia OEL - TWA 5 mg/m<sup>3</sup>

Lithuania OEL - TWA 5 mg/m<sup>3</sup>

### Exposure Controls

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.  
**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Wear impervious gloves if skin contact is possible.

**Eyes:** Wear safety glasses as minimum protection.

**Skin:** Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Liquid	<b>Color:</b>	Clear
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture
<b>Solvent Solubility:</b>	No data available		

## SAFETY DATA SHEET

Material Name: TRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection  
Revision date: 19-Nov-2014

Page 4 of 7

Version: 5.1

### 9. PHYSICAL AND CHEMICAL PROPERTIES

**Water Solubility:** No data available  
**pH:** 6.5 - 8.5  
**Melting/Freezing Point (°C):** No data available  
**Boiling Point (°C):** No data available.  
**Partition Coefficient: (Method, pH, Endpoint, Value)**

**MnBrLP2086**

No data available

**L-Histidine**

No data available

**SODIUM CHLORIDE**

No data available

**Polysorbate 80**

No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions**

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**General Information:** Toxicological properties of the formulation have not been fully investigated. The information included in this section describes the potential hazards of the individual ingredients.

**Short Term:** In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted.

**Known Clinical Effects:** Based on clinical trials in humans, possible adverse effects following exposure to this compound may include:

**Acute Toxicity: (Species, Route, End Point, Dose)**

## SAFETY DATA SHEET

Material Name: TRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection  
Revision date: 19-Nov-2014

Page 5 of 7

Version: 5.1

### 11. TOXICOLOGICAL INFORMATION

#### L-Histidine

Rat Oral LD 50 > 15 g/kg  
Rat Para-periosteal LD 50 > 2g/kg  
Mouse Oral LD 50 > 15g/kg  
Mouse Intravenous LD 50 > 2g/kg

#### SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>  
Rat Oral LD 50 3g/kg  
Mouse Oral LD 50 4g/kg  
Rabbit Dermal LD 50 > 10g/kg

#### Polysorbate 80

Rat Intravenous LD 50 1790 mg/kg  
Mouse Oral LD 50 25g/kg

#### Irritation / Sensitization: (Study Type, Species, Severity)

#### SODIUM CHLORIDE

Skin Irritation Rabbit Mild  
Eye Irritation Rabbit Mild

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### MnBrLP2086

9 Week(s) Rabbit Intramuscular 400 ug/dose/2weeks NOEL None identified

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### MnBrLP2086

Fertility and Embryonic Development Rabbit Intramuscular \* 200 ug/dose NOEL Reproductive toxicity, Developmental toxicity

#### Reproductive & Development Toxicity Comments:

MnBrLP2086: \* NOTE: 4 doses -17 and 4 days prior to mating, gestation days 10 and 24.

#### Carcinogen Status:

Not listed as a carcinogen by IARC, NTP or US OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

## SAFETY DATA SHEET

Material Name: TRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection  
Revision date: 19-Nov-2014

Page 6 of 7

Version: 5.1

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transportation as per defining criteria in the international transportation regulations and the shipper's knowledge of the material.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

**Additional Information:** This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

**Canada - WHMIS: Classifications**

**WHMIS hazard class:**

None required

**Polysorbate 80**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

**L-Histidine**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-745-3

**MnBrLP2086**

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

## SAFETY DATA SHEET

Material Name: TRUMENBA (Meningococcal Group B  
Vaccine) Suspension for intramuscular injection  
Revision date: 19-Nov-2014

Page 7 of 7

Version: 5.1

### 15. REGULATORY INFORMATION

California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

#### SODIUM CHLORIDE

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

### 16. OTHER INFORMATION

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

**Reasons for Revision:** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

**Revision date:** 19-Nov-2014  
Product Stewardship Hazard Communication

**Prepared by:** Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**